Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition
Anna K. Dewan(Vanderbilt University Medical Center), Nicole R. LeBoeuf(Dana-Farber Brigham Cancer Center), Scott R. Granter(Brigham and Women's Hospital), Robin Joyce(Beth Israel Deaconess Medical Center), Saagar Jadeja(Brigham and Women's Hospital), Matthew S. Davids(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Victor Huang(Brigham and Women's Hospital), Daniel Q. Bach(Universitat de Barcelona), Sameer Gupta(Brigham and Women's Hospital)
Cited by 10
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k